Does routine testing for primary aldosteronism improve long-term outcomes in patients following stroke?
Routine testing for primary aldosteronism is underutilized in stroke care pathways, missing a treatable cause of hypertension that could prevent recurrent events.
These findings highlight a missed opportunity to identify a treatable cause of hypertension in patients at high risk of recurrent cerebrovascular events. Routine testing for primary aldosteronism in stroke care pathways may improve long-term outcomes through targeted intervention.
McCarthy et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: